Literature DB >> 31363172

A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model.

Chuanjian Wu1, Manman Wu1, Minglong Liang1, Sidong Xiong2, Chunsheng Dong3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31363172      PMCID： PMC6804750          DOI： 10.1038/s41423-019-0264-7

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  11 in total

1.  Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.

Authors:  Kefang Liu; Shuguang Tan; Yan Chai; Danqing Chen; Hao Song; Catherine Wei-Hong Zhang; Yi Shi; Jun Liu; Wenjie Tan; Jianxin Lyu; Shan Gao; Jinghua Yan; Jianxun Qi; George F Gao
Journal:  Cell Res       Date:  2016-08-30       Impact factor: 25.617

2.  The altered PD-1/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg/Th17 imbalance in pre-eclampsia.

Authors:  Yonghong Zhang; Zhaozhao Liu; Mei Tian; Xiaohui Hu; Liling Wang; Jinlu Ji; Aihua Liao
Journal:  Cell Mol Immunol       Date:  2017-09-11       Impact factor: 11.530

3.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

4.  Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library.

Authors:  Longlong Luo; Shi Wang; Xiaoling Lang; Tingting Zhou; Jing Geng; Xinying Li; Chunxia Qiao; Jiannan Feng; Beifen Shen; Ming Lv; Yan Li
Journal:  Cell Mol Immunol       Date:  2016-08-08       Impact factor: 11.530

Review 5.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

Authors:  Lieping Chen; Xue Han
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

6.  Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.

Authors:  Jason R Smedberg; Marlena M Westcott; Maryam Ahmed; Douglas S Lyles
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

7.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Authors:  David L Porter; Wei-Ting Hwang; Noelle V Frey; Simon F Lacey; Pamela A Shaw; Alison W Loren; Adam Bagg; Katherine T Marcucci; Angela Shen; Vanessa Gonzalez; David Ambrose; Stephan A Grupp; Anne Chew; Zhaohui Zheng; Michael C Milone; Bruce L Levine; Jan J Melenhorst; Carl H June
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

8.  Programmed contraction of CD8(+) T cells after infection.

Authors:  Vladimir P Badovinac; Brandon B Porter; John T Harty
Journal:  Nat Immunol       Date:  2002-06-03       Impact factor: 25.606

9.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Authors:  Antoni Ribas; Reinhard Dummer; Igor Puzanov; Ari VanderWalde; Robert H I Andtbacka; Olivier Michielin; Anthony J Olszanski; Josep Malvehy; Jonathan Cebon; Eugenio Fernandez; John M Kirkwood; Thomas F Gajewski; Lisa Chen; Kevin S Gorski; Abraham A Anderson; Scott J Diede; Michael E Lassman; Jennifer Gansert; F Stephen Hodi; Georgina V Long
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

10.  PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.

Authors:  Masami Iwasa; Takeshi Harada; Asuka Oda; Ariunzaya Bat-Erdene; Jumpei Teramachi; Hirofumi Tenshin; Mohannad Ashtar; Masahiro Oura; Kimiko Sogabe; Kengo Udaka; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Kumiko Kagawa; Shuji Ozaki; Masahiro Abe
Journal:  Oncotarget       Date:  2019-03-08
View more
  8 in total

1.  A single dose of recombinant VSV-RABVG vaccine provides full protection against RABV challenge.

Authors:  Minglong Liang; Zongmei Wang; Chuanjian Wu; Sidong Xiong; Ling Zhao; Chunsheng Dong
Journal:  Virol Sin       Date:  2022-02-25       Impact factor: 6.947

2.  Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model.

Authors:  Maria Vitale; Filippo Scialò; Margherita Passariello; Eleonora Leggiero; Anna D'Agostino; Lorella Tripodi; Laura Gentile; Andrea Bianco; Giuseppe Castaldo; Vincenzo Cerullo; Claudia De Lorenzo; Lucio Pastore
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

Review 3.  The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?

Authors:  Shunchuan Zhang; Samuel D Rabkin
Journal:  Expert Opin Drug Discov       Date:  2020-12-14       Impact factor: 6.098

Review 4.  The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Authors:  Xiaohu Zheng; Yaqi Wu; Jiacheng Bi; Yingying Huang; Ying Cheng; Yangyang Li; Yuwei Wu; Guoshuai Cao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 11.530

5.  Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes.

Authors:  Dmitry V Chouljenko; Jun Ding; I-Fang Lee; Yanal M Murad; Xuexian Bu; Guoyu Liu; Zahid Delwar; Yi Sun; Sheng Yu; Ismael Samudio; Ronghua Zhao; William Wei-Guo Jia
Journal:  Biomedicines       Date:  2020-11-09

Review 6.  Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.

Authors:  Roland E Kontermann; Guy Ungerechts; Dirk M Nettelbeck
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 7.  Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.

Authors:  Yi Ren; Jia-Meng Miao; Yuan-Yuan Wang; Zheng Fan; Xian-Bin Kong; Long Yang; Gong Cheng
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

Review 8.  An overview of development in gene therapeutics in China.

Authors:  Dawei Wang; Kang Wang; Yujia Cai
Journal:  Gene Ther       Date:  2020-06-11       Impact factor: 5.250
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.